CymaBay Therapeutics Inc. (NASDAQ:CBAY) has a beta value of 0.11 and has seen 2.43 million shares traded in the recent trading session. The company, currently valued at $538.78M, closed the recent trade at $7.38 per share which meant it gained $0.77 on the day or 11.57% during that session. The CBAY stock price is 3.12% off its 52-week high price of $7.15 and 77.37% above the 52-week low of $1.67. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.33 million shares traded. The 3-month trading volume is 764.63K shares.
The consensus among analysts is that CymaBay Therapeutics Inc. (CBAY) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 9 have rated it as a Hold, with 9 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.3.
CymaBay Therapeutics Inc. (NASDAQ:CBAY) trade information
Sporting 11.57% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the CBAY stock price touched $7.38 or saw a rise of 0.67%. Year-to-date, CymaBay Therapeutics Inc. shares have moved 5.42%, while the 5-day performance has seen it change 1.54%. Over the past 30 days, the shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) have changed 43.07%. Short interest in the company has seen 1.74 million shares shorted with days to cover at 4.61.
Wall Street analysts have a consensus price target for the stock at $10.44, which means that the shares’ value could jump 29.31% from the levels at last check today. The projected low price target is $8.00 while the price target rests at a high of $17.00. In that case, then, we find that the latest price level in today’s session is -130.35% off the targeted high while a plunge would see the stock gain -8.4% from the levels at last check today.
CymaBay Therapeutics Inc. (CBAY) estimates and forecasts
Figures show that CymaBay Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 109.84% over the past 6 months, with this year growth rate of 3.94%, compared to -4.40% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 9.10% and 17.60% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.20% over the past 5 years.
CymaBay Therapeutics Inc. is expected to release its next earnings report between March 15 and March 20 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
CymaBay Therapeutics Inc. (NASDAQ:CBAY)’s Major holders
Insiders own 0.39% of the company shares, while shares held by institutions stand at 76.51% with a share float percentage of 76.81%. Investors are also buoyed by the number of investors in a company, with CymaBay Therapeutics Inc. having a total of 147 institutions that hold shares in the company. The top two institutional holders are Avoro Capital Advisors LLC with over 10.3 million shares worth more than $30.39 million. As of Jun 29, 2022, Avoro Capital Advisors LLC held 12.16% of shares outstanding.
The other major institutional holder is Tcg Crossover Management, Llc, with the holding of over 5.91 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $17.42 million and represent 6.97% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.83% shares in the company for having 2.4 million shares of worth $7.07 million while later fund manager owns 1.0 million shares of worth $2.96 million as of Jun 29, 2022, which makes it owner of about 1.19% of company’s outstanding stock.